AAN 2024 | Immunomodulatory therapies for treating status epilepticus

Clio Rubinos, MD, University of North Carolina at Chapel Hill, Chapel Hill, NC, discusses immunomodulatory therapies for the treatment of patients with status epilepticus. In patients with a diagnosis of new onset refactory status epilepticus (NORSE) – which may be associated with fevers preceding the presentation of the disease (FIRES patients)– corticosteroids, IV immunoglobulin (IVIG), and plasmapheresis are some of the strategies which can be employed within 72 hours of presentation. In patients outside of these disease classifications, neurosteroids such as allopregnanolone and ganaxolone are being investigated, with varying degrees of success. This interview took place at the American Academy of Neurology (AAN) Annual Meeting 2024 in Denver, CO.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.